Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended 30 September 2008
Issuance Date: 22 October 2008
GSK reported Q3 2008 results, highlighting a transition in its pharmaceutical portfolio due to generic competition in the US, offset by growth in vaccines, emerging markets, and consumer healthcare. The company continues to pursue portfolio renewal with 10 product launches in 2008 and maintains a pipeline of approximately 30 late-stage assets.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Turnover (£m) | 5,882 | 5,476 | 17,442 | 16,742 |
| Business Performance EPS (p) | 25.2p | 27.7p | 78.0p | 82.1p |
| Statutory EPS (p) | 20.1p | 23.7p | 69.2p | 74.7p |
| Operating Profit - Business Perf. (£m) | 1,979 | 2,199 | 6,153 | 6,554 |
| Operating Profit - Statutory (£m) | 1,657 | 1,910 | 5,559 | 6,005 |
| Net Cash Inflow from Ops (£m) | 1,893 (Q3) | 1,838 (Q3) | 5,067 (9mo) | 4,777 (9mo) |
| Net Debt (£bn) | 8.6 (as of 30 Sep 2008) |
Note: Growth percentages in the source text are primarily presented at Constant Exchange Rates (CER). Business Performance excludes restructuring charges.
Material Changes vs. Prior Period
- Revenue: Total turnover grew 7% in sterling terms for Q3 but declined 3% at CER. Pharmaceuticals turnover fell 4% at CER, driven by a 13% decline in the US due to generic competition. Conversely, Vaccines grew 12% and Consumer Healthcare grew 3% (5% excluding alli).
- Profitability: Business Performance EPS declined 9% at CER but rose 6% in sterling terms due to currency movements. Statutory EPS fell 30% at CER, impacted by £322m in restructuring charges.
- Product Performance:
- Declines: Lamictal (-59%), Wellbutrin (-67%), Coreg IR (-93%), and Avandia (-23%) due to generic entry or controversy.
- Growth: Seretide/Advair (+7%), Valtrex (+21%), and Cervarix (new sales of £43m).
- Balance Sheet: Net debt increased by £2.6bn to £8.6bn, reflecting share buybacks (£3.3bn in 9 months) and dividend payments. Net assets decreased by £2.1bn, partly due to a widening pension deficit to £1.192bn.
Guidance, Outlook, and Risks
- Guidance: GSK expects a mid-single digit percentage decline in Business Performance EPS at constant exchange rates for the full year 2008.
- Dividends: The Board declared a third interim dividend of 14p per share (an 8% increase). ADR holders receive 47.4796 cents per ADS.
- Capital Allocation: The company completed £3.3bn in share repurchases in the first nine months and expects to reach ~£4bn by year-end. No significant repurchases are expected in 2009 to maintain flexibility for investment opportunities.
- Operational Excellence: The company is on track to realize annual savings of at least £350m in 2008 and £700m by 2010.
- Risks & Contingencies:
- Legal: Aggregate provision for legal disputes is £1.2bn. Key matters include Avandia securities litigation (motion to dismiss granted, plaintiffs appealed), Paxil settlement (terms confidential), and patent challenges regarding Combivir and Treximet.
- Tax: A Notice of Deficiency was received from the IRS regarding inter-company financing; a petition was filed in US Tax Court. The effective tax rate for Q3 rose to 29.8% due to UK Finance Act changes.
- Market: Generic competition in the US remains a significant headwind for mature pharmaceutical brands.
Investor Verification Checklist
- Generic Impact: Verify the sustainability of sales declines in key US franchises (Lamictal, Wellbutrin, Avandia) and the timeline for portfolio renewal.
- Avandia Controversy: Monitor the status of the Avandia securities litigation appeal and the impact of ongoing safety controversies on sales.
- Pension Deficit: Review the drivers of the increased pension deficit (£1.192bn) and potential future cash requirements for funding.
- Share Buyback Strategy: Confirm the cessation of significant share repurchases in 2009 and the criteria for future M&A or investment opportunities.
- Legal Provisions: Assess the adequacy of the £1.2bn legal provision given the uncertainty of outcomes in major patent and product liability cases.